CO2019009221A2 - Composición farmacéutica que comprende selexipag - Google Patents
Composición farmacéutica que comprende selexipagInfo
- Publication number
- CO2019009221A2 CO2019009221A2 CONC2019/0009221A CO2019009221A CO2019009221A2 CO 2019009221 A2 CO2019009221 A2 CO 2019009221A2 CO 2019009221 A CO2019009221 A CO 2019009221A CO 2019009221 A2 CO2019009221 A2 CO 2019009221A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- aqueous
- pharmaceutical composition
- selexipag
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017055406 | 2017-03-08 | ||
| PCT/EP2018/055551 WO2018162527A1 (en) | 2017-03-08 | 2018-03-07 | Pharmaceutical composition comprising selexipag |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019009221A2 true CO2019009221A2 (es) | 2019-08-30 |
Family
ID=61655736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0009221A CO2019009221A2 (es) | 2017-03-08 | 2019-08-27 | Composición farmacéutica que comprende selexipag |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP3592391B1 (ru) |
| JP (1) | JP6964679B2 (ru) |
| KR (1) | KR102593075B1 (ru) |
| CN (1) | CN110430900B (ru) |
| AR (1) | AR111570A1 (ru) |
| AU (1) | AU2018229750B2 (ru) |
| BR (1) | BR112019018420A2 (ru) |
| CA (1) | CA3055010A1 (ru) |
| CL (1) | CL2019002511A1 (ru) |
| CO (1) | CO2019009221A2 (ru) |
| CR (1) | CR20190455A (ru) |
| DO (1) | DOP2019000250A (ru) |
| EA (1) | EA201992074A1 (ru) |
| EC (1) | ECSP19072294A (ru) |
| ES (1) | ES2880009T3 (ru) |
| IL (1) | IL269061A (ru) |
| JO (1) | JOP20190204A1 (ru) |
| MA (1) | MA47816A (ru) |
| MX (1) | MX2019010598A (ru) |
| NI (1) | NI201900090A (ru) |
| PE (1) | PE20191492A1 (ru) |
| PH (1) | PH12019502033A1 (ru) |
| PL (1) | PL3592391T3 (ru) |
| SG (1) | SG11201907804QA (ru) |
| TW (1) | TWI764996B (ru) |
| WO (1) | WO2018162527A1 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022532076A (ja) * | 2019-05-06 | 2022-07-13 | アクテリオン ファーマシューティカルズ リミテッド | サルコイドーシス関連肺高血圧症の治療方法 |
| US20220323437A1 (en) * | 2019-06-11 | 2022-10-13 | Actelion Pharmaceuticals Ltd | Methods for treating pulmonary arterial hypertension |
| CA3154802A1 (en) * | 2019-10-23 | 2021-04-29 | Marc Patrik SCHRADER | Pharmaceutical composition comprising selexipag |
| WO2021152060A1 (en) | 2020-01-31 | 2021-08-05 | Actelion Pharmaceuticals Ltd | Controlled release selexipag composition |
| TW202239408A (zh) * | 2021-01-29 | 2022-10-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡𠯤衍生物的醫藥組成物 |
| WO2022215045A1 (en) * | 2021-04-08 | 2022-10-13 | Glenmark Pharmaceutical Limited | Lyophilized composition comprising selexipag |
| WO2023131608A1 (en) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Controlled release compositions |
| WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
| WO2023238952A1 (ja) * | 2022-06-10 | 2023-12-14 | 日本新薬株式会社 | 医薬組成物 |
| WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
| WO2024133620A1 (en) | 2022-12-22 | 2024-06-27 | Actelion Pharmaceuticals Ltd | In vitro dissolution test |
| WO2024194449A1 (en) | 2023-03-23 | 2024-09-26 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising a diphenylpyrazine derivative |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI316055B (ru) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| DK2246336T3 (da) | 2008-02-28 | 2020-07-20 | Nippon Shinyaku Co Ltd | Fibroseinhibitor |
| WO2009154246A1 (ja) | 2008-06-19 | 2009-12-23 | 日本新薬株式会社 | 勃起不全治療剤 |
| WO2009157397A1 (ja) | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤 |
| CN102065864B (zh) | 2008-06-23 | 2012-11-21 | 日本新药株式会社 | 炎性肠病治疗剂 |
| WO2009157396A1 (ja) | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 脊柱管狭窄症治療剤 |
| KR102705198B1 (ko) | 2009-06-26 | 2024-09-11 | 니뽄 신야쿠 가부시키가이샤 | 결정 |
| WO2011024874A1 (ja) | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
| EP2741738A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Sustained release composition of prostacyclin |
| US20150272874A1 (en) | 2012-10-29 | 2015-10-01 | Cardio Incorporated | Pulmonary disease-specific therapeutic agent |
| CA2923844C (en) * | 2013-09-11 | 2022-07-26 | Arsia Therapeutics, Inc. | Liquid protein formulations containing organophosphates |
| GB201400412D0 (en) * | 2014-01-10 | 2014-02-26 | Heart Biotech Ltd | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension |
| WO2017029594A1 (en) | 2015-08-17 | 2017-02-23 | Dr. Reddy's Laboratories Limited | Processes for preparation of selexipag and its amorphous form |
| EP3192502A1 (en) * | 2016-01-15 | 2017-07-19 | Sandoz Ag | Pharmaceutical composition of selexipag |
-
2017
- 2017-06-16 JO JOP/2019/0204A patent/JOP20190204A1/ar unknown
-
2018
- 2018-03-06 TW TW107107374A patent/TWI764996B/zh active
- 2018-03-07 MX MX2019010598A patent/MX2019010598A/es unknown
- 2018-03-07 MA MA047816A patent/MA47816A/fr unknown
- 2018-03-07 CN CN201880016540.5A patent/CN110430900B/zh active Active
- 2018-03-07 PL PL18711258T patent/PL3592391T3/pl unknown
- 2018-03-07 AR ARP180100522A patent/AR111570A1/es unknown
- 2018-03-07 AU AU2018229750A patent/AU2018229750B2/en not_active Expired - Fee Related
- 2018-03-07 EA EA201992074A patent/EA201992074A1/ru unknown
- 2018-03-07 CA CA3055010A patent/CA3055010A1/en active Pending
- 2018-03-07 WO PCT/EP2018/055551 patent/WO2018162527A1/en unknown
- 2018-03-07 EP EP18711258.6A patent/EP3592391B1/en active Active
- 2018-03-07 KR KR1020197029059A patent/KR102593075B1/ko active IP Right Grant
- 2018-03-07 JP JP2019548608A patent/JP6964679B2/ja active Active
- 2018-03-07 ES ES18711258T patent/ES2880009T3/es active Active
- 2018-03-07 CR CR20190455A patent/CR20190455A/es unknown
- 2018-03-07 PE PE2019001788A patent/PE20191492A1/es unknown
- 2018-03-07 SG SG11201907804QA patent/SG11201907804QA/en unknown
- 2018-03-07 BR BR112019018420A patent/BR112019018420A2/pt active Search and Examination
-
2019
- 2019-08-27 CO CONC2019/0009221A patent/CO2019009221A2/es unknown
- 2019-09-02 IL IL26906119A patent/IL269061A/en unknown
- 2019-09-02 CL CL2019002511A patent/CL2019002511A1/es unknown
- 2019-09-06 PH PH12019502033A patent/PH12019502033A1/en unknown
- 2019-09-06 NI NI201900090A patent/NI201900090A/es unknown
- 2019-10-02 DO DO2019000250A patent/DOP2019000250A/es unknown
- 2019-10-04 EC ECSENADI201972294A patent/ECSP19072294A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR111570A1 (es) | 2019-07-31 |
| DOP2019000250A (es) | 2020-09-15 |
| CN110430900A (zh) | 2019-11-08 |
| SG11201907804QA (en) | 2019-09-27 |
| CN110430900B (zh) | 2023-09-19 |
| MA47816A (fr) | 2020-01-15 |
| EP3592391B1 (en) | 2021-04-21 |
| US20200129506A1 (en) | 2020-04-30 |
| KR20190122803A (ko) | 2019-10-30 |
| CA3055010A1 (en) | 2018-09-13 |
| TW201842910A (zh) | 2018-12-16 |
| JP6964679B2 (ja) | 2021-11-10 |
| BR112019018420A2 (pt) | 2020-04-14 |
| AU2018229750A1 (en) | 2019-09-12 |
| IL269061A (en) | 2019-11-28 |
| WO2018162527A1 (en) | 2018-09-13 |
| MX2019010598A (es) | 2019-10-15 |
| NI201900090A (es) | 2020-03-11 |
| TWI764996B (zh) | 2022-05-21 |
| JOP20190204A1 (ar) | 2019-09-05 |
| ES2880009T3 (es) | 2021-11-23 |
| ECSP19072294A (es) | 2019-11-30 |
| KR102593075B1 (ko) | 2023-10-23 |
| PL3592391T3 (pl) | 2021-11-02 |
| CR20190455A (es) | 2019-11-12 |
| EP3592391A1 (en) | 2020-01-15 |
| AU2018229750B2 (en) | 2023-11-23 |
| JP2020509070A (ja) | 2020-03-26 |
| PH12019502033A1 (en) | 2020-06-15 |
| EA201992074A1 (ru) | 2020-02-27 |
| CL2019002511A1 (es) | 2020-01-17 |
| PE20191492A1 (es) | 2019-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019009221A2 (es) | Composición farmacéutica que comprende selexipag | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| NI201900041A (es) | 1, 2, 4-triazolonas 2, 4, 5-trisustituidas | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EA202090890A1 (ru) | Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия | |
| CO2020001244A2 (es) | Derivados de quinolina para tratar infecciones con helmintos | |
| EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| CL2022000998A1 (es) | Inhibidores de las cinasas raf | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| EA201990820A1 (ru) | Способы лечения митохондриальных и метаболических нарушений | |
| CY1120530T1 (el) | Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση | |
| UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
| CO6400235A2 (es) | Tensiactivos reconstituidos que tienen propiedades mejoradas | |
| EA202090536A1 (ru) | Кристаллические формы 3-замещенного 1,2,4-оксадиазола | |
| ECSP22040921A (es) | Composición farmacéutica que comprende selexipag | |
| BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| BR112012026509A2 (pt) | "novos derivados de benzamida" | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112017019431A2 (pt) | material de implante de compósito | |
| CL2008002060A1 (es) | Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras. | |
| DOP2023000170A (es) | Formas cristalinas de (4s)24cloro4etil73fluoro35metoxi32,5dioxo14(trifluorometil)32h6aza3(4,1)piridina1(1)[1,2,3]triazola2(1,2),7(1)dibencenaheptafano74carboxamida |